SCHEMBL1086328

SCHEMBL1086328

O=C1OC2(CCN(C(=S)NCc3ccccc3)CC2)CN1Cc1cccc(Br)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.47
KMT2A Q03164 7/20 0.43
MEN1 O00255 6/20 0.43
LMNA P02545 6/20 0.43
MAPT P10636 4/20 0.43
HTT P42858 1/20 0.43
ALDH1A1 P00352 5/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PKM P14618 2/20 0.40
KDM4E B2RXH2 2/20 0.39
TACR2 P21452 1/20 0.39
TACR1 P25103 1/20 0.39
GAA P10253 2/20 0.39
FAAH O00519 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1086488 0.87 KDM4E (0.42) KMT2AMEN1HTTALDH1A1SMN1; SMN2
SCHEMBL1086332 0.86 POLB (0.46) POLBKMT2AMEN1LMNAMAPT
SCHEMBL4261752 0.85 LMNA (0.48) KMT2AMEN1LMNAHTTALDH1A1
SCHEMBL1086125 0.84 KDM4E (0.45) KMT2AMEN1HTTALDH1A1SMN1; SMN2
SCHEMBL1085948 0.82 POLB (0.46) POLBKMT2AMEN1LMNAMAPT
Beclamide SCHEMBL1086327 0.82 KDM4E (0.38) POLBLMNASMN1; SMN2KDM4ETACR2
SCHEMBL4263516 0.82 SMN1; SMN2 (0.47) POLBKMT2AMEN1LMNAALDH1A1
SCHEMBL4256335 0.81 SIRT2 (0.42) SMN1; SMN2KDM4ETACR2TACR1FAAH
SCHEMBL1086487 0.81 SIRT2 (0.42) KMT2AMEN1SMN1; SMN2KDM4ETACR2
SCHEMBL4257384 0.81 LMNA (0.38) POLBKMT2ALMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US claimed
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP claimed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US claimed
EP-1910381-A2 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-04-16 EP claimed
WO-2007000325-A2 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-01-04 WO claimed
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US disclosed
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP disclosed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs DDO, DAO, OTC POLB 2624/4885KMT2A 4267/4885MEN1 1008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.